Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study.
about
Brain metastasis in human epidermal growth factor receptor 2-positive breast cancer: from biology to treatmentMolecular and Genetic Predictors of Breast-to-Brain Metastasis: Review and Case PresentationProfiling and targeting HER2-positive breast cancer using trastuzumab emtansineRecent advances in the development of anti-HER2 antibodies and antibody-drug conjugatesStrategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials.Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA.Current approaches to the treatment of metastatic brain tumours.Trastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema.Progress in the biological understanding and management of breast cancer-associated central nervous system metastases.Maintenance treatment of trastuzumab for patients with advanced breast cancer to achieve long term survival: two case reports and literature review.Leptomeningeal metastases in breast cancer.Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier.Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study.Prognostic factors and survival of patients with brain metastasis from breast cancer who underwent craniotomy.Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2).Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases.Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remissionLapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer.Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors.Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer.Effect of HER2 status on distant recurrence in early stage breast cancerMulticenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphomaHER-2 Expression in Brain Metastases from Colorectal Cancer and Corresponding Primary Tumors: A Case Cohort Series.FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies.Development of a preclinical therapeutic model of human brain metastasis with chemoradiotherapy.Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era.Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic TargetsRole of lapatinib alone or in combination in the treatment of HER2-positive breast cancerComplement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma.Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells.Chemoprevention for brain metastases.The Rationale for Targeted Therapies and Stereotactic Radiosurgery in the Treatment of Brain Metastases.Brain metastases: an overview.Failure patterns according to molecular subtype in patients with invasive breast cancer following postoperative adjuvant radiotherapy: long-term outcomes in contemporary clinical practice.Lapatinib: an oral dual tyrosine kinase inhibitor for HER-2-positive breast cancer.Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions.HER2-positivity rates in breast cancer: no variation over time when clinicopathological features and testing are stable.Improved Aptamers for the Diagnosis and Potential Treatment of HER2-Positive Cancer.
P2860
Q26751008-728AD93D-4E47-4415-8E14-C6925C4EE7ECQ26800626-A5F9DDA3-9A8F-436A-9357-2F0311CF474CQ27015048-90294FDD-B71A-4A8F-9308-B6E3126A9DD9Q28083123-1BC6EEC7-B4EC-497E-99F7-865B0DDE45A7Q30857631-78E17D02-F984-4A9D-975A-8FB1BEF5EF14Q33683140-BAD05B87-1D34-48C5-9754-3921112ECAA2Q33696559-18FB9D70-507A-4ACB-86B3-414904AD2DCDQ33753475-6FECBE6B-84E7-44C4-804E-7E84C8C008D9Q33777436-A907A0F9-6D2B-42B3-BB03-03760CECE9A0Q34130140-9E1AAB13-8633-4A81-AFAB-4A5346EDEC6EQ34650605-21DB87B7-6AE4-4B75-81F8-A0FFFC807516Q35608531-9E6021F1-825E-4402-8B67-4D9A34A852FBQ35683537-35D16256-EEDF-496C-92D4-7F1C95C01FF6Q35915735-752330EB-9111-4068-A339-027B30439E38Q35928878-E4887E39-25D9-4555-9764-4FE7578C083AQ36027093-1444BCEC-7B4C-4EDF-8A7A-94EF30B1280EQ36107363-4E6A581E-0577-496D-8F8F-E02E834C7BC4Q36212437-C5A212D1-ABE0-48C9-ABF2-639F69E636D7Q36371783-11C26600-4F87-4785-933C-73F87C6097FCQ36372466-332143EE-2918-4753-B814-BD167C7426D9Q36385329-73AEB163-1D1C-44A5-8F0F-39E0A441848CQ36408570-1D4C7835-2B3D-449E-B54D-F12168FA0312Q36530791-4BB07731-36A6-4B23-92AF-47DA38FE42B4Q36584818-57CAD18D-4562-4A21-88BB-50375AC338C9Q36655951-F4DBBAD1-0E92-4D04-995F-F71A3EB57330Q36688951-6A8D3945-75DD-40BB-9DC0-14BD66050F6CQ36820588-6FC29A09-F997-4E89-A6FC-52000C8F1F0AQ37020382-58A329E3-4222-4A7D-8EBF-1CB0CC9F13F4Q37028708-8FD95B78-BC97-42D3-85E4-3DE0FBEEAC64Q37355762-EC1E6AAE-67D2-4E67-8AA6-2410CF8DA863Q37620923-06A2B02C-A364-4C96-9023-57285E3C974CQ37694756-C4D713B1-FA4C-4747-8E52-F9E7080EECB5Q37946748-62FEB40C-76DC-4684-9B2A-51ADB7EA4A12Q38289478-ADDC08C3-6D50-41BD-A944-F393D1C8F304Q38317417-8D2719CC-1AD4-4E87-9856-CF4BA7DC9743Q38896813-B6ABE40B-D819-4E69-8F68-25DAE2DD6269Q38992588-1AF64EC1-A9E6-41AE-9B62-ED73D20C3502Q39652258-9862108A-A72F-4985-9285-3C54149B4FC6Q40391145-2BA046D8-A919-4553-95A5-2995C431E78EQ42070603-04264735-29BA-4E25-BD5A-90B8F66B7BB9
P2860
Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Multifactorial central nervous ...... n-based cancer registry study.
@ast
Multifactorial central nervous ...... n-based cancer registry study.
@en
type
label
Multifactorial central nervous ...... n-based cancer registry study.
@ast
Multifactorial central nervous ...... n-based cancer registry study.
@en
prefLabel
Multifactorial central nervous ...... n-based cancer registry study.
@ast
Multifactorial central nervous ...... n-based cancer registry study.
@en
P2093
P2860
P356
P1433
P1476
Multifactorial central nervous ...... on-based cancer registry study
@en
P2093
Andrea Ardizzoni
Cecilia Bozzetti
Daniele Zanoni
Elisa Fontana
Enrico Maria Silini
Maria Michiara
Michele Panebianco
P2860
P304
P356
10.1002/CNCR.25771
P407
P577
2010-11-10T00:00:00Z